Wockhardt shareholders reject resolution on related party transaction

Published On 2023-08-18 08:00 GMT | Update On 2023-08-18 08:00 GMT

New Delhi: Shareholders of pharma firm Wockhardt Ltd have rejected a resolution on a related party transaction that seeks to allow the company to raise up to Rs 1,600 crore from its promoter group firm Khorakiwala Holdings and Investments Pvt Ltd. At the company's annual general meeting held on August 14, the company had put ten resolutions, including the adoption of audited financial statements and the re-appointment of Murtaza Khorakiwala as Managing Director, for approval by the shareholders, all of which were approved except the related party transaction.

All the resolutions mentioned in the notice of the 24th annual general meeting stand passed with the requisite majority except Resolution No 7 (approval of material related party transactions), which was not approved by the members, company secretary Virendra Bhatt said in the consolidated scrutiniser's report.

In a regulatory filing, Wockhardt said out of the total valid votes cast, 50.13 per cent was against the ordinary resolution for approving the material-related party transaction, while 49.87 per cent was in favour.

In the notice for the AGM, Wockhardt had sought approval of its members for the company to avail secured/unsecured short-term/long-term funding facilities by way of loans, credit facilities, debt instruments or in any other form, from Khorakiwala Holdings and Investments Pvt Ltd (KHIPL) on arms-length basis, such that the maximum amount of the funds borrowed from KHIPL, along with any outstanding amount borrowed shall not in aggregate exceed Rs 1,600 crore.

The company had explained that Sebi regulations had modified the threshold for determination of material-related party transactions, requiring prior shareholders' approval to the lower of Rs 1,000 crore or 10 per cent of the annual consolidated turnover of the listed entity as per its last audited financial statements.

"Since the upper limit of the maximum drawdown proposed to be availed from KHIPL pursuant to the overdraft facility exceeds the threshold for seeking shareholders' approval under the listing regulations, it is proposed to seek approval from the public shareholders of the company for entering into/continuing with the aforesaid facility," it had stated

Read also: Wockhardt plans to roll out two vaccines within year from UK facility as part of a tie-up with SII

Article Source : PTI

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Wockhardt shareholders reject resolution on related party transaction

Similar News

Russia's Enteromix Cancer Vaccine Shows 100% Success in Trial, Awaits Final Nod for Public Use

Mankind Pharma wins CDSCO nod to start Phase 1 trials of Autoimmune drug candidate

India seeks to boost drug exports to semi regulated markets in Africa, Latin America, Southeast Asia

Jubilant Ingrevia appoints Sonia Dharap as Vice President - Sales, Business Development (US)

EMA warns of sharp rise in illegal medicines sold in EU

Indegene opens new center in Pune, boosts India presence

Indian medical devices share increased from 10% to 30% of domestic requirements in last 5 years: DoP Secretary

AstraZeneca announces Rs 176 crore investments in India to expand Chennai GITC